Basket trial results suggest advanced FGFR-altered solid tumors may benefit from FGFR inhibitor pemigatinib

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


Jashodeep Datta, a researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been awarded a grant from the U.S. Department of Defense’s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer. The $800,000, three-year grant is the first DoD award to Sylvester to study pancreatic cancer.
Researchers at MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a phase I clinical trial.